Abstract: The present invention relates to a process for preparing nanofibers and nanofiber membranes and to the nanofibers and nanofiber membranes obtainable by such process.

Abstract: The present invention relates to covalently cross-linked glycosylated mucin nanoparticles and the use thereof for the delivery and release of active ingredients, markers and/or biomolecules. The subject matter of the invention also relates to covalently cross-linked glycosylated mucin nanoparticles comprising at least one compound selected from an active ingredient, a marker and a biomolecule. The invention further relates to a method for preparing covalently cross-linked glycosylated mucin nanoparticles, optionally comprising at least one compound selected from an active ingredient, a marker and a biomolecule.

Abstract: The present invention relates to a new process for the preparation of Panobinostat and intermediates thereof.

Abstract: The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (Efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, C3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.

Abstract: A process for producing a photosensitive resin for 3D printing includes: (i) treating a vegetable oil with a polyol to form a monoglyceride, (ii) reacting the monoglyceride of step (i) with an unsaturated reagent to form a liquid resin with viscosity lower than 20 Pa·s at the temperature of 20° C., and (iii) mixing the liquid resin with a comonomer and a photoinitiator, as well as the photosensitive resin for 3D printing obtainable from such process and the 3D object obtainable from such photosensitive resin.

Abstract: The present invention relates to a process for preparing nanofibers and nanofiber membranes and to the nanofibers and nanofiber membranes obtainable by such process.

Abstract: Disclosed are proteins derived from the HGF/SF which are able to induce activation of the tyrosine kinase receptor MET and their uses, in particular to promote tissue regeneration. Further disclosed are nucleic acid molecules coding such protein, expression vectors containing such nucleic acid molecule, host cells containing such expression vectors, and related compositions.

Abstract: A two-photon excited fluorescence microscope including a laser source configured to emit a light beam and an optical arrangement configured to receive the light beam from the laser source. The optical arrangement is configured to shape the light beam so that, at an output of the microscope, the light beam is substantially collimated in a first transverse direction perpendicular to the propagation direction of the light beam at the microscope output and is focused in a second transverse direction perpendicular to the first transverse direction and to the propagation direction, thereby forming a line parallel to the first transverse direction.

Abstract: The present invention allows a screening method for identifying novel drugs for the treatment of tuberculosis as well as a diagnostic method for identifying clinical strains that are resistant to these novel drugs. In particular, the present invention relates to a method for screening in vitro drug candidates for the treatment of tuberculosis by interfering with the arabinogalactan biosynthesis, the said method comprising a step of putting into contact a Mycobacterium tuberculosis cell culture over-expressing a protein that performs the transformation of decaprenyl-P-ribose to decaprenyl-P-arabinose and that can be encoded by rv3790 gene or homologues thereof or any open-reading artificial frame whose gene product is identical or homologue to Rv3790 protein, with a drug candidate and then evaluating the percentage of inhibition caused by the drug candidate against a control in an assay test, such as an antibacterial test or an enzymatic test.

Abstract: Tranylcypromine derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of histone demethylases LSD1 and LSD2, such as the diseases characterized by deregulation of gene transcription, cell differentiation and proliferation, e.g. tumors, viral infections, are herein described. These compounds belong to the structural formula (I) wherein A and R3 are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to compositions containing them and to therapeutic use thereof.

Abstract: Tranylcypromine derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of histone demethylases LSD1 and LSD2, such as the diseases characterized by deregulation of gene transcription, cell differentiation and proliferation, e.g. tumors, viral infections, are herein described. These compounds belong to the structural formula (I) wherein A and R3 are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to compositions containing them and to therapeutic use thereof.

Abstract: Disclosed are antibodies that block the binding of fibronectin protein to fibronectin. Also disclosed are site specifically-mutated and truncated peptide epitopes derived from the fnbA and fnbB genes of Staphylococcus aureus, the fnbA and fnbB genes of Streptococcus dysgalactiae, and the sfb gene of Streptococcus pyogenes, and nucleic acid segments encoding these peptides and epitopes. The anti-(fibronectin binding site) antibodies, peptides and epitopes that give rise to antibodies that block the binding of fibronectin binding proteins to fibronectin, and DNA segments encoding these proteins and are of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of streptococcal and staphylococcal colonization in animals or humans. These. DNA segments and the peptides derived therefrom are proposed to be of use directly in the preparation of vaccines and also for use as carrier proteins in vaccine formulations.

Abstract: The present invention concerns the use of platelet lysate for treating and/or preventing mucositis. Moreover, a mucoadhesive composition comprising such a platelet lysate for the therapy and/or prevention of mucositis and of corneal lesions is described.

Abstract: Surface proteins are provided which generate polyclonal and monoclonal antibodies which are cross-reactive to both coagulase-positive staphylococcus bacteria, such as S. aureus and to coagulase-negative bacteria, such as S. epidermidis and S. hemolyticus. The antibodies may be generated from surface proteins that have been isolated on the basis of characteristics that may be common between S. aureus and coagulase-negative staphylococci, or the A domains of those surface proteins, and these recombinant surface proteins are used to generate the cross-reactive antibodies. Vaccines comprising an immunologically effective amount of the proteins are also provided, and these vaccines are used in methods for the treatment or protection against a wide variety of staphylococcal infections.

Abstract: The present invention is based on the identification of new mutations in KCNQ1 (also termed KvLQTI), KCNH2 (also termed HERG), SCN5A, KCNE1 (also termed minK), KCNE2 (also termed MiRP) genes that encode ionic channels involved in cardiac electrical activity and are potentially responsible for the Long QT Syndrome. According to a main aspect, the invention relates to nucleic acids, oligonucleotides and polynucleotides and mRNA, containing sequences of KCNQ1, KCNH2 SCN5A, KCNE1, KCNE2 genes and cDNAs in a mutated form and to respective variant proteins thereof. A preferred embodiment of the present invention is represented by a diagnostic method based on the identification of a group of about 70 non-private mutations in the KCNQ1, KCNH2 and SCN5A genes, detected at high frequency.

Abstract: Antibodies to the CNA protein and to other regions from the collagen binding domain, including domain CNA19, are provided, and antibodies produced in this manner have been shown to be cross reactive to both Staphylococcus aureus and Staphylococcus epidermidis bacteria and which can thus be used in the prevention and treatment of infections caused by both of these types of bacteria. In addition, medical instruments can be treated using the antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the proteins are advantageous because they are cross-reactive and may thus be administered to patients so as to reduce or prevent severe infection by staphylococcal bacteria of more than one species.

Abstract: A phase change memory device includes a plurality of phase-change memory cells, arranged in rows and columns, phase-change memory cells arranged on the same column being connected to a same bit line; a plurality of first selectors, each coupled to a respective phase-change memory cell; an addressing circuit for selectively addressing at least one of the bit lines, one of the first selectors, and the phase-change memory cell connected to the addressed bit line and to the addressed first selector; and a regulated voltage supply circuit, selectively connectable to the addressed bit line, for supplying a bit line voltage. The bit line voltage is correlated to a first control voltage on the addressed first selector, coupled to the addressed phase-change memory cell.

Abstract: The present invention relates to a method for estimating or predicting anti-tumor activity of a compound and for estimating or predicting the tumor growth in mammals; the estimation comprises a) measuring the tumor weight in time; b) measuring the concentration of the compound in time; c) calculating kinetic parameters of the tumor growth: -a parameter (L0), representative of the portion of tumor cells present at the instant t0=0 that succeeds in taking root and in starting tumor cells proliferation in the mammals; -an index (?0) of the production rate of tumor cells during an exponential phase of tumor growth; -an index (?1) of tumor cells mass produced in the time unit during a linear phase of the tumor growth; and pharmacodynamic parameters: -an index (K1) of tumor cells death rate; -an index (K2) of the potency of the compound; and d) calculating tumor growth curves.

Abstract: Polyclonal and monoclonal antibodies which are cross-reactive to both coagulase-positive staphylococcus bacteria, such as S. aureus and to coagulase-negative bacteria, such as S. epidermidis and S. hemolyticus, are provided which can recognize surface proteins from both coagulase-positive and coagulase negative staph bacteria. The antibodies may be generated from surface proteins that have been isolated on the basis of characteristics that may be common between S. aureus and coagulase-negative staphylococci, and these recombinant surface proteins are used to generate the antibodies of the invention. There is also provided vaccines and methods which utilize these proteins and antibodies for the treatment or protection against a wide variety of staphylococcal infections.